The Upcoming Biotech Battle

Santini, Laura
April 2003
Investment Dealers' Digest;4/21/2003, Vol. 69 Issue 16, p9
Trade Publication
Reports on the interest shown by U.S. generic drug makers in biotechnology drugs which are in danger of losing patent protection. Predicted competition between biotech companies and generic drug makers; Legal and regulatory issues; Perceived support for generic drug makers from the U.S. government.


Related Articles

  • Mid-year, generics and biotechs are thriving. Arnold, Matthew // Medical Marketing & Media;Oct2003, Vol. 38 Issue 10, p32 

    Reports on the increase in sales of biotechnology and generic drugs, according to June 2002 update on the global market pharmaceutical by IMS Health. Therapy sales breakdown; Generics penetration in the U.S.

  • Where Biotechs, Generics Converge. Reed, Vita // Orange County Business Journal;04/16/2001, Vol. 24 Issue 16, p60 

    Focuses the convergence of generic and biotechnology drug makers for Sicor Inc. in Irvine, California. Similarity between Sicor and Teva Pharmaceutical Industries Ltd.; Assets of biotech companies; Concerns on the intellectual property protection.

  • Controversy clouds biogenerics market. Chater, Amanda // Drug Store News;8/28/2006, Vol. 28 Issue 10, p60 

    The article reports on the controversy surrounding biogenerics, generic versions of biotechnology drugs. Biotechnology manufacturers cites the difficulty of producing an exact replica of a biotechnology drug, made from living cells with large molecules. The advantages of biogeneric drugs include...

  • Under Review.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p142 

    Highlights several issues critical to the pharmaceutical industry that need to be addressed. Need to balance companies' intellectual property rights with patients' right to access lower-priced generics; Pharmacovigilance and fast-track registration; Biotechnology issues.

  • U.S. companies lagging in biogenerics. Chater, Amanda // Drug Store News;9/25/2006, Vol. 28 Issue 12, p36 

    The article reports on the approval for the production of biogenerics where the U.S. is lagging behind Europe despite being the biggest pharmaceutical market in the world. Experts say that it is because these drugs are more difficult and expensive to classify and manufacture. The success of...

  • European Generic Firms Mount Biosimilars Push. O'Donnell, Peter // BioWorld International;12/5/2007, Vol. 12 Issue 49, p4 

    This article reports on a public campaign that was launched by the European generic medicines association European Generic Medicines Association (EGA) to win acceptance of biosimilars or the generic versions of biotechnology medicines. The guide being distributed by generic companies is...

  • Global Pharma: A Mid-Year Health Check. Lewis, Graham // European Pharmaceutical Executive;Jul/Aug2005, p30 

    The article provides global updates in the pharmaceutical industry for 2005. The growth in the industry continues to see a single digit global revenue. In the U.S., which is the largest market has a single digit growth, while Europe and Japan are likely to continue in high and low single digit...

  • Mergers & acquisitions (M&A) in the pharmaceutical industry: the wheel keeps on turning. Hornke, Matthias; Mandewirth, Sven // Journal of Business Chemistry;May2010, Vol. 7 Issue 2, p67 

    In this article, the authors discuss mergers and acquisitions (M&A) in the pharmaceutical industry. They note that the global M&A transaction volume fell in 2009, as did the global share of financial investors in purchase volume. They mention that generic drug manufacturers are becoming...

  • Research & Markets: The Essential 2011 Global Pharmaceuticals Industry Guide With Profiles of the Leading Companies in the Industry.  // Biomedical Market Newsletter;5/14/2011, p216 

    The article focuses on the "Global: Pharmaceuticals Industry Guide," which contains the profiles of the leading companies in the industry. The reports provides expert analysis with distinct chapters for generics, life sciences tools & services, pharmaceuticals, biotechnology and life sciences....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics